Therapeutic antibodies that block inhibitory immune checkpoint receptors or their ligands (CTLA-4, PD-1, PD-L1; collectively termed immune checkpoint inhibitor (CPI) therapies) have shown dramatic results in the treatment of melanoma and other cancers17–20 achieving durable responses, but only in a minority of patients21. Here, PDCD1 is linked to melanoma.